StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,400 shares, an increase of 45.5% from the January 15th total of 4,400 shares. Based on an average daily trading volume, of 4,400 shares, the days-to-cover ratio is currently 1.5 days.
StageZero Life Sciences Stock Performance
SZLSF stock traded up $0.00 during midday trading on Monday, hitting $0.05. 1,000 shares of the stock traded hands, compared to its average volume of 6,350. The firm has a market cap of $5.60 million, a P/E ratio of -0.76 and a beta of 0.90. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.08 and a quick ratio of 0.04. The stock's fifty day simple moving average is $0.05 and its 200-day simple moving average is $0.06. StageZero Life Sciences has a 1-year low of $0.04 and a 1-year high of $0.20.
Get
StageZero Life Sciences alerts:
StageZero Life Sciences Company Profile
(Get Rating)
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.
Featured Stories
- Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
- Should Medtronic's Recent Colibri Patent Controversy Concern You?
- Checkpoint Software Helps Cyber Security Stocks Bottom
- Under Armour Stock, Gap and Crap, Here's Why
- Is Chevron Positioned To Take Energy Sector Leadership?
- What Does the Consumer Price Index Measure?
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
StageZero生命科学有限公司(OTCMKTS:SZLSF-GET Rating)在1月份看到空头股数的显著增长。截至1月31日,空头股数共有6400股,比1月15日的4400股增加了45.5%。以日均成交量4,400股计算,目前天数与回补比率为1.5天。
StageZero生命科学类股表现
周一午盘,SZLSF股价上涨0.00美元,触及0.05美元。该股有1000股易手,而其平均成交量为6350股。该公司市值为560万美元,市盈率为-0.76,贝塔系数为0.90。该公司的债务权益比为0.44,流动比率为0.08,速动比率为0.04。该股的50日简单移动均线为0.05美元,200日简单移动均线为0.06美元。StageZero生命科学的一年低点为0.04美元,一年高位为0.20美元。
到达
StageZero生命科学警报:
StageZero生命科学公司简介
(获取评级)
StageZero生命科学有限公司致力于专利分子诊断测试的开发和商业化,用于检测疾病和个性化健康管理,重点是癌症相关适应症。其产品包括哨兵原理和科隆哨兵。该公司是由刘忠钦和K。
专题报道
- 免费获取StockNews.com关于StageZero生命科学(SZLSF)的研究报告
- 美敦力最近的Colibri专利争议是否应该引起您的关注?
- Checkpoint软件帮助网络安全类股触底
- 在装甲库存、缺口和垃圾下,这就是为什么
- 雪佛龙做好了引领能源行业的准备吗?
- 消费者物价指数衡量的是什么?
接受StageZero生命科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对StageZero生命科学和相关公司的最新新闻和分析师评级的每日简要摘要。